TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A South Asian physician says she was screened for diabetes at a BMI of 23 but was denied a GLP-1 weight-loss drug at BMI 26.5 because she did not meet the usual U.S. thresholds of 30, or 27 with a weight-related condition. Her MedPage Today opinion argues that clinical guidance, drug labels and insurer rules use inconsistent definitions of obesity; the account does not establish a change in coverage policy.
South Asian physician Hamayle Saeed says she was screened for diabetes after her BMI passed 23 but was told she did not qualify for a GLP-1 weight-loss drug at a BMI of 26.5, because she had neither a BMI of 30 nor a BMI of 27 with a weight-related condition. In an October 31 MedPage Today opinion, Saeed argues that the disparity reflects a gap between diabetes-risk guidance for Asian patients and the criteria insurers use to cover obesity medicines.
Saeed describes her experience as a personal account, not a report of a new coverage decision. She writes that her doctor began diabetes screening at the BMI threshold of 23, while her request for a GLP-1 receptor agonist was denied under the standard U.S. eligibility thresholds she cites. She says she had no diabetes diagnosis and did not meet the alternate BMI threshold of 27 tied to a weight-related condition.
The article says Asian-specific risk thresholds are grounded in differences in average body composition and disease risk. It cites World Health Organization action points of BMI 23 and 27.5 for Asian populations and a study of nearly 1.5 million adults in England that estimated the BMI at which South Asian adults reached the diabetes risk seen in white adults at BMI 30 was 23.9. These population-level findings do not establish an individual’s diagnosis or treatment eligibility.
Saeed also points to a 2025 study of semaglutide 2.4 mg, known as Wegovy, conducted in South Korea and Thailand. The trial used a local obesity definition beginning at BMI 25; participants lost 16% of body weight, compared with 3.1% in the placebo group. A post hoc analysis of 68 participants who began below BMI 30 reported average losses of 17.6% among 45 semaglutide recipients and 4.4% among 23 placebo recipients. The article notes that the smaller subgroup analysis does not by itself establish U.S. insurance coverage criteria.
The Gap Between Risk and Coverage
The account highlights how screening thresholds and drug-access rules can diverge. A person may be considered at elevated diabetes risk at a BMI below the threshold commonly used by insurers for anti-obesity medication. For Asian patients, whose average metabolic risk may appear at lower BMI levels, that mismatch could mean earlier screening without corresponding access to treatment.
The distinction matters because clinical guidance, FDA indications and payer policies are not interchangeable. A guideline that recommends screening does not automatically qualify someone for a prescription or compel an insurer to pay. Saeed argues that coverage forms continue to rely on BMI cutoffs even as some clinical standards and drug-label wording have shifted toward broader definitions. The source does not document a specific insurer’s response to her case or establish that all plans apply identical rules.
The opinion also describes shrinking public coverage for weight-loss GLP-1s: it says Medi-Cal ended that coverage in January and MassHealth followed in July. Those examples make the question consequential beyond one patient, but the article does not provide detailed plan documents or assess exceptions, appeals, or coverage for other indications such as diabetes.
Products Worth Considering
EGO POWER+ Cordless Leaf Blower, 765 CFM, with 5.0Ah Battery (LB7654)
Husqvarna 460 Rancher Gas Chainsaw, 24-Inch Bar
Solo Stove Ranger 2.0 15-Inch Smokeless Fire Pit with Stand
As an affiliate, we earn on qualifying purchases.
How BMI Rules Diverged
Body mass index is a ratio of weight to height, but it does not directly measure body fat or its distribution. Saeed cites 2025 international obesity guidance estimating that, at a similar level of body fat, Asian adults may have a BMI two to three points lower than white adults. She says visceral fat and lower muscle mass can contribute to higher metabolic risk at lower BMI levels, while stressing a broader policy concern: thresholds developed around one population may not translate well to others.
The opinion says the American Diabetes Association’s 2026 Standards of Care advise clinicians to assess excess adiposity using cutoffs appropriate to ethnicity, including for South Asian patients. It also says updated U.S. labels for Wegovy and tirzepatide (Zepbound) describe indicated patients as adults with obesity, or adults with overweight and a weight-related condition, without specifying a BMI number in that wording. Saeed argues that numerical cutoffs nevertheless remain in trial criteria and insurer prior-authorization forms.
She cites a 2026 analysis of 352 GLP-1 trials that found BMI criteria disproportionately limited Asian participation: a BMI cutoff of 30 would have made 13.5% of Asian American adults and 7.2% of Korean adults eligible, compared with 41.5% of non-Asian American adults. Those are eligibility estimates reported in the opinion, not evidence that every trial or insurer uses the same rule.
“The ADA guideline that flags me for annual diabetes screening and the prior authorization form that denies me the drug are describing the same 26.5. Only one of them was written with an Asian body in mind.”
— Hamayle Saeed, MD, in MedPage Today
Coverage Rules Still Vary
The source is an opinion essay and first-person account; it does not include the patient’s denial letter, identify the insurer, or provide its explanation beyond the eligibility thresholds Saeed describes. It is not clear whether an appeal, alternative coverage route, or different plan would change the outcome. The report also does not establish how widely insurers have revised their rules following changes in clinical guidance or drug-label wording.
The evidence cited has limits. Results from a South Korean and Thai study, particularly its smaller post hoc subgroup below BMI 30, do not alone prove that the same treatment effect or eligibility policy should apply to every patient or U.S. population. The article’s discussion of ethnic BMI thresholds also does not settle how clinicians and payers should define obesity for an individual patient.
Policy Changes Remain Unspecified
Saeed’s article calls attention to a policy question but does not announce a pending rule change, insurer review, or government action. The next developments to watch are whether U.S. payers revise prior-authorization criteria, how they apply ethnicity-sensitive clinical guidance, and whether updated trial evidence influences coverage decisions. For now, the account describes a gap between risk screening and access rather than a confirmed change to eligibility.
Key Questions
Why was the physician screened at a BMI of 23?
Saeed says diabetes screening began at that level because guidance recognizes that Asian Americans can face elevated diabetes risk at lower BMIs. Screening guidance is not the same as a diagnosis or a medication-coverage rule.
Why did she say she did not qualify for a GLP-1?
According to her account, the criteria applied to her request required a BMI of 30, or a BMI of 27 with at least one weight-related condition. At BMI 26.5, without diabetes, she said she met neither threshold.
Does an Asian-specific screening threshold guarantee GLP-1 coverage?
No. A screening recommendation does not automatically establish eligibility for a prescription or require an insurer to cover it. Coverage depends on the applicable drug indication and payer rules, which the article says can retain numerical BMI cutoffs.
What does the STEP 11 study show?
The 2025 study in South Korea and Thailand tested semaglutide using a local obesity threshold of BMI 25. The report says participants lost 16% of body weight on average versus 3.1% with placebo; a smaller post hoc subgroup below BMI 30 also showed greater average loss with semaglutide. The study does not itself determine U.S. insurance coverage.
Source: medpagetoday.com
